<DOC>
	<DOCNO>NCT00751114</DOCNO>
	<brief_summary>The primary objective demonstrate superiority insulin glargine sitagliptin reduce Glycosylated Hemoglobin A1c ( HbA1c ) baseline end treatment period . Secondary objective ass effect insulin glargine comparison sitagliptin : - HbA1c level - Fasting Plasma Glucose ( FPG ) - 7-point plasma glucose ( PG ) profile - Percentage patient HbA1c &lt; 7 % &lt; 6.5 % Safety objectives consist : - Hypoglycemia occurrence - Body weight - Overall safety</brief_summary>
	<brief_title>Evaluation Insulin Glargine Versus Sitagliptin Insulin-naive Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>With type 2 diabetes diagnose least 6 month , Not previously treat insulin , On metformin least 3 month stable minimal dose 1 g/day least 2 month HbA1c ≥ 7 &lt; 11 % , Body Mass Index ( BMI ) 25 45 kg/m² inclusively , Ability willingness perform plasma glucose ( PG ) monitoring use Sponsorprovided PG meter complete patient diary , Signed informed consent obtain prior study procedure , Willingness ability comply study protocol . Treatment oral antidiabetic drug metformin within last 3 month , Previous treatment combination metformin + sulfonylurea 1 year , Previous treatment Glucagon Like Peptide1 ( GLP1 ) agonists DiPeptidyl Peptidase ( DPP ) IV inhibitor , FPG ( assessed central laboratory measurement ) ≥ 280 mg/dL ( 15.4 mmol/L ) , Diabetes type 2 diabetes ( e.g . secondary pancreatic disorder , drug chemical agent intake ... ) , Pregnant lactate woman ( woman childbearing potential must negative pregnancy test study entry medically approve contraception method ) , Inpatient care , Active proliferative retinopathy , define photocoagulation vitrectomy occurrence 6 month prior visit 1 , unstable ( rapidly progress ) retinopathy may require photocoagulation surgical treatment study ( optic fundus examination perform within 2 year prior study entry ) , Impaired renal function : serum creatinine ≥ 1.5 mg/dL ( ≥ 133µmol/L ) ≥ 1.4 mg/dL ( ≥ 124 µmol/L ) men woman , respectively , History sensitivity study drug drug similar chemical structure , Impaired hepatic function : alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) &gt; 3 x upper limit normal range , Treatment systemic corticosteroid within 3 month prior study entry likelihood require treatment study permit study ( exception : case chronic adrenal insufficiency , systemic glucosteroids accept disease stable treatment dose stable least 3 month study entry ) , Alcohol drug abuse within last year , Night shift worker , Presence condition ( medical , psychological , social geographical ) , current anticipate investigator feel would compromise patient 's safety limit patient successful participation study , Treatment weight loss medication ( e.g . sibutramine , orlistat , rimonabant ) within last 3 month , Participation another clinical trial within month prior visit 1 , History pancreatitis .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>